Olema Pharmaceuticals

Olema Oncology announces FDA clearance for OP-3136, a KAT6 inhibitor, to proceed into Phase 1 clinical trials in early 2025.

Olema Pharmaceuticals announced FDA clearance of its IND application for OP-3136, a KAT6 inhibitor for breast and other cancers, with plans to initiate a Phase 1 clinical trial in early 2025.

Olema Pharmaceuticals to present Phase 1b/2 study data of palazestrant (OP-1250) combined with ribociclib at SABCS 2024. Palazestrant is a dual-action ER antagonist and degrader for ER+/HER2- advanced breast cancer, with FDA Fast Track designation.

Switch the Market flag for targeted data from your country of choice. Right-click on the chart to open the Interactive Chart menu. Use up/down arrows to move through symbols.

Ascentage Pharma appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors, effective November 25, 2024.